Search research articles
Contact Us
Filters
Showing results (751-760 of 1,211) with videos related to
Page
of 122
Sort By:
Circulation
|
November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
JACC. Heart Failure
|
July 13, 2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
Scott D Solomon, Pardeep S Jhund, Brian L Claggett, et al.
European Heart Journal
|
August 27, 2021
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P Curtain, Kieran F Docherty, Pardeep S Jhund, et al.
Journal of Cardiac Failure
|
November 27, 2024
Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trials
Kieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
European Journal of Heart Failure
|
June 27, 2023
Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction
Mingming Yang, Toru Kondo, Carly Adamson, et al.
American Journal of Nephrology
|
January 19, 2011
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease
Ravi Thadhani, Evan Appelbaum, Yuchiao Chang, et al.
Circulation
|
July 28, 2010
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
Anne-Catherine Pouleur, Ebrahim Barkoudah, Hajime Uno, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Journal of Diabetes Research
|
January 17, 2019
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration
Jelena P Seferovic, Rhonda Bentley-Lewis, Brian Claggett, et al.
European Heart Journal
|
August 2, 2015
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Pardeep S Jhund, Michael Fu, Edmundo Bayram, et al.
Page
of 122
Search research articles
Search
Showing results (751-760 of 1,211) with videos related to
Sort By:
Page
of 122
Circulation
|
November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
JACC. Heart Failure
|
July 13, 2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
Scott D Solomon, Pardeep S Jhund, Brian L Claggett, et al.
European Heart Journal
|
August 27, 2021
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P Curtain, Kieran F Docherty, Pardeep S Jhund, et al.
Journal of Cardiac Failure
|
November 27, 2024
Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trials
Kieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
European Journal of Heart Failure
|
June 27, 2023
Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction
Mingming Yang, Toru Kondo, Carly Adamson, et al.
American Journal of Nephrology
|
January 19, 2011
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease
Ravi Thadhani, Evan Appelbaum, Yuchiao Chang, et al.
Circulation
|
July 28, 2010
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
Anne-Catherine Pouleur, Ebrahim Barkoudah, Hajime Uno, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Journal of Diabetes Research
|
January 17, 2019
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration
Jelena P Seferovic, Rhonda Bentley-Lewis, Brian Claggett, et al.
European Heart Journal
|
August 2, 2015
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Pardeep S Jhund, Michael Fu, Edmundo Bayram, et al.
Page
of 122